Merck, Orna Therapeutics sign circular RNA collaboration deal valued at up to $3.65B

The companies will work together to discover, develop, and commercialize multiple oRNA programs, including vaccines and therapeutics, for infectious diseases and cancer.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.